Neuronetics (STIM) Projected to Post Quarterly Earnings on Tuesday

Neuronetics (NASDAQ:STIM) will likely be posting its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Neuronetics to announce earnings of ($0.11) per share and revenue of $40.1740 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:30 AM ET.

Neuronetics (NASDAQ:STIM) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.01. Neuronetics had a negative return on equity of 139.83% and a negative net margin of 24.48%.The firm had revenue of $34.45 million during the quarter, compared to analyst estimates of $34.17 million. On average, analysts expect Neuronetics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Neuronetics Stock Up 4.6%

STIM opened at $1.81 on Tuesday. The company has a debt-to-equity ratio of 3.59, a quick ratio of 1.50 and a current ratio of 1.67. The firm has a market cap of $125.96 million, a price-to-earnings ratio of -3.35 and a beta of 1.06. Neuronetics has a twelve month low of $0.80 and a twelve month high of $4.85. The firm’s 50-day simple moving average is $1.45 and its 200-day simple moving average is $1.53.

Analysts Set New Price Targets

STIM has been the topic of a number of research analyst reports. Wall Street Zen upgraded Neuronetics from a “sell” rating to a “hold” rating in a research report on Sunday, July 12th. BTIG Research assumed coverage on Neuronetics in a research note on Monday, July 20th. They issued a “buy” rating and a $5.00 target price for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Neuronetics in a report on Thursday, June 18th. Finally, Citigroup reiterated a “market outperform” rating on shares of Neuronetics in a research report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $4.00.

Insider Buying and Selling at Neuronetics

In related news, major shareholder Jorey Chernett acquired 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The stock was purchased at an average price of $1.17 per share, for a total transaction of $117,000.00. Following the transaction, the insider directly owned 10,553,988 shares of the company’s stock, valued at approximately $12,348,165.96. This trade represents a 0.96% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 8.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Neuronetics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Neuronetics by 3.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,832,118 shares of the company’s stock valued at $7,732,000 after purchasing an additional 89,504 shares during the last quarter. UBS Group AG lifted its holdings in Neuronetics by 580.7% in the third quarter. UBS Group AG now owns 2,164,831 shares of the company’s stock valued at $5,910,000 after buying an additional 1,846,801 shares during the period. Lane Generational LLC bought a new position in Neuronetics in the fourth quarter valued at approximately $2,353,000. Balyasny Asset Management L.P. grew its holdings in Neuronetics by 6.5% during the 2nd quarter. Balyasny Asset Management L.P. now owns 1,509,099 shares of the company’s stock worth $5,267,000 after acquiring an additional 92,048 shares during the period. Finally, Wexford Capital LP raised its position in shares of Neuronetics by 83.1% during the 3rd quarter. Wexford Capital LP now owns 1,177,225 shares of the company’s stock valued at $3,214,000 after acquiring an additional 534,155 shares during the last quarter. 53.59% of the stock is owned by institutional investors and hedge funds.

Neuronetics Company Profile

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.